SOX2 and cancer: Although NSC and ESC are adversely affected by increases in the levels of SOX2, other studies have reported that breast [18], prostate [19] and lung [20] cancer cells engineered to constitutively express elevated levels of SOX2 (∼3- to 4-fold) exhibit enhanced growth and tumorigenicity.